Mechanisms and pharmacological manipulation of eosinophil accumulation in vivo.
The presence of eosinophils and their products in tissues is frequently associated with the pathogenesis of allergic inflammation. A better understanding of how these cells are recruited from the microcirculation will help in the development of therapies targeted at allergic disorders. Here, Mauro Teixeira, Timothy Williams and Paul Hellewell describe the current concepts of eosinophil accumulation, examine the potential ways of modulating this process, and discuss whether antagonists of eosinophil-specific mediators or functional antagonists would be the preferred therapies.
Teixeira
M M
MM
Department of Applied Pharmacology, National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, London, UK.
Williams
T J
TJ
Hellewell
P G
PG
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D018821:CD18 Antigens / Q000494:pharmacology / Q000627:therapeutic use; D002449:Cell Aggregation; D002465:Cell Movement; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D004804:Eosinophils / Q000187:drug effects / Q000502:physiology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D006634:Histamine H1 Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006967:Hypersensitivity / Q000209:etiology*; D018799:Intercellular Adhesion Molecule-1 / Q000494:pharmacology / Q000627:therapeutic use; D007377:Interleukin-3 / Q000378:metabolism; D015848:Interleukin-5 / Q000378:metabolism
D000911:Antibodies, Monoclonal; D018821:CD18 Antigens; D004791:Enzyme Inhibitors; D006634:Histamine H1 Antagonists; D007377:Interleukin-3; D015848:Interleukin-5; D018799:Intercellular Adhesion Molecule-1; D016178:Granulocyte-Macrophage Colony-Stimulating Factor